title: [ATP-tumor chemosensitivity assay directed chemotherapy in patients with cervical cancer].
abstract: OBJECTIVE
  To select suitable chemotherapy for cervical cancer patients by ATP-tumor chemosensitivity assay.
  
  
  METHODS
  Seventy-two hospitalized patients with cervical cancer between July 2007 and October 2009 were enrolled. The patients were randomly divided into a trial group (n=35) and a control group (n=37). ATP-TCA was used to detect the sensitivity of 35 samples of cervical cancer in the trial group to 6 combined chemotherapy regimens. The chemotherapy regimen in the trial group was confirmed by the results of susceptibility testing and that in the control group was confirmed by clinical experience. One-year recurrence rate and 3- year survival rate of two groups were compared after 3 year follow-up.
  
  
  RESULTS
  ATP-TCA was measured in 32 of the 35 patients in the trial group. The sensitive patients for paclitaxel+carboplatin, paclitaxel+oxaliplatin, bleomycin+ifosfamide+cisplatin, bleomycin+vincristine+cisplatin, fluorouracil+cisplatin, and gemcitabine+cisplatin were 20, 18, 17, 18, 17, and 21, respectively. There was no significant difference in the 1-year recurrence between the two groups (P>0.05), while the 3-year survivors in the trial group were more than those in the control group (P<0.05).
  
  
  CONCLUSIONS
  ATP-TCA method is good for patients with cervical cancer because it is sensitive, effective, and individualized.
authors.affiliation: Department of Gynecology and Obstetrics, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052,China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Zhang
authors.forename: Qian
authors.initials: Q
authors.lastname: Zhao
authors.forename: Yanan
authors.initials: Y
authors.lastname: Jiang
authors.forename: Zhongfu
authors.initials: Z
authors.lastname: Yuan
authors.forename: Li
authors.initials: L
authors.lastname: Yang
mesh_terms: D000255:Adenosine Triphosphate; D000971:Antineoplastic Combined Chemotherapy Protocols; D001761:Bleomycin; D016190:Carboplatin; D002945:Cisplatin; D003841:Deoxycytidine / Q000031:analogs & derivatives; D004354:Drug Screening Assays, Antitumor; D005260:Female; D005472:Fluorouracil; D006801:Humans; D007069:Ifosfamide; D009364:Neoplasm Recurrence, Local; D017239:Paclitaxel; D015996:Survival Rate; D002583:Uterine Cervical Neoplasms / Q000188:drug therapy*; D014750:Vincristine; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D001761:Bleomycin; D014750:Vincristine; D000255:Adenosine Triphosphate; D016190:Carboplatin; D017239:Paclitaxel; D002945:Cisplatin; D005472:Fluorouracil; D007069:Ifosfamide; D000093542:Gemcitabine